M&A · Healthcare · Laboratory Analytical Instruments
Quanterix Corp to acquire Akoya Biosciences, Inc.
Announced Jan 10, 2025 · Closed Jul 8, 2025
Deal value—
Premium19.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Quanterix Corp (QTRX)
- Target
- Akoya Biosciences, Inc. (AKYA)
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Jul 8, 2025
Deal protections
- Break fee (target pays)
- $7.0M
- Reverse fee (buyer pays)
- $9.0M
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Goldman Sachs
- To the target
- Perella Weinberg
Sector context · Healthcare
- Comparable deals
- 94 in the prior 24 months
- Premium
- 19.0% vs. 66.0% sector median
- EV / Adj. EBITDA
- Sector median 14.5x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedJan 10, 2025
- Proxy filedApr 15, 2025
- Definitive proxyApr 15, 2025
- Shareholder voteJul 7, 2025
- ClosedJul 8, 2025
Valuation · fairness opinions
Trading comparables$0.60$1.50
Trading comparables$9.75$16.33
Trading comparables$0.84$1.88
Trading comparables$10.26$15.94
Precedent transactions$0.57$1.64
Implied value per Akoya Biosciences, Inc. share by analysis · DCF discount rate 12.5%–15.5%.